Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $3.25 per share versus the Zacks Consensus Estimate of a loss of $3.61. This compares to a loss of $3.32 per share a year ago.
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Madrigal Pharmaceuticals, Inc. receives a Sell rating, citing high valuation and intensifying MASH competition despite Rezdiffra's initial commercial success. Rezdiffra achieved $958.4m in 2025 sales with ~36,250 patients, but MDGL profitability remains elusive as operating expenses outpace revenue growth. SG&A and R&D costs are expected to rise in 2026, while no specific guidance has been provided, and consensus sees potential Q1 revenue softness.
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC
Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,000 shares of the biopharmaceutical company's stock, valued at approximately $55,039,000. Alkeon Capital Management LLC owned
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday
Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying 43% upside. Rezdiffra's rapid commercialization and first-mover advantage in the MASH market underpin robust sales growth, with Q3 net sales at $287.3M and >29,500 active patients. Geographic expansion in Europe, pipeline catalysts (F4 trial), and under-diagnosis of MASH provide a long growth runway and potential for upside surprises.
MDGL Strengthens MASH Franchise With New Genetic Approaches
Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
